Gustafson H, Wijkström H, Nyman C, Brolin J, Borgström E, Tribukait B
Department of Urology, Danderyd Hospital, Stockholm, Sweden.
Scand J Urol Nephrol Suppl. 1991;138:187-91.
Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C. Treatment lasted for one year and patients were evaluated after a mean follow-up of 35 to 47 months if progression had not occurred. Mitomycin C was superior in reducing the recurrence rate. Progressive disease was observed in 17 patients regardless of therapy but in all patients DNA aneuploidy could be identified at a risk factor.
60例Ta期和T1期膀胱癌患者被随机分为单纯切除术治疗组以及接受阿霉素或丝裂霉素C切除并灌注治疗组。治疗持续一年，若未出现病情进展，则在平均随访35至47个月后对患者进行评估。丝裂霉素C在降低复发率方面更具优势。无论接受何种治疗，均有17例患者出现疾病进展，但在所有患者中，DNA非整倍体均可被识别为一个危险因素。
